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A complex interplay of genetic and environmental risk factors influence global brain 
structural alterations associated with brain health and disease. Epigenome-wide association 
studies (EWAS) of global brain imaging phenotypes have the potential to reveal the 
mechanisms of brain health and disease and can lead to better predictive analytics through 
the development of risk scores. 
We perform an EWAS of global brain volumes in Generation Scotland using 
peripherally measured whole blood DNA methylation (DNAm) from two assessments, (i) at 
baseline recruitment, ~6 years prior to MRI assessment (N=672) and (ii) concurrent with MRI 
assessment (N=565). Four CpGs at baseline were associated with global cerebral white 
matter, total grey matter, and whole-brain volume (Bonferroni p≤7.41×10−8, βrange= -1.46x10-6 
to 9.59x10-7). These CpGs were annotated to genes implicated in brain-related traits, 
including psychiatric disorders, development, and ageing. We did not find significant 
associations in the meta-analysis of the EWAS of the two sets concurrent with imaging at 
the corrected level. 
These findings reveal global brain structural changes associated with DNAm measured 
~6 years previously, indicating a potential role of early DNAm modifications in brain structure. 
Although concurrent DNAm was not associated with global brain structure, the nominally 
significant findings identified here present a rationale for future investigation of associations 
between DNA methylation and structural brain phenotypes in larger population-based 
samples. 




Global brain structure is influenced by genetic and environmental factors, and has 2 
previously been associated with health and disorder traits across the lifetime (1–3). For 3 
instance, changes in global grey and white matter have been observed in a number of 4 
psychiatric and neurological disorders, including schizophrenia (4), major depressive disorder 5 
(MDD) (3), bipolar disorder (5), Rett syndrome (6), and Alzheimer’s disease (7). Previous 6 
studies have also found age-related reductions in both grey and white matter (8,9). 7 
Such global brain structural changes in both health and disease may reflect genetic 8 
and environmental factors and their impact. While previous studies have focussed on 9 
revealing the genetic architecture of brain structure, there are now opportunities to explore 10 
genetic and environmental risk factors through epigenetics, which correlate with changes in 11 
gene expression by modulating the genome in different cell types, without altering the 12 
underlying genome sequence (10). One such process, DNA methylation (DNAm), implicates 13 
the covalent addition of a methyl group to a cytosine nucleotide followed by guanine in DNA, 14 
resulting in Cytosine-phosphate-Guanine (CpG) sites (10). 15 
DNAm is modulated by both genetic and environmental factors, and may thus aid in 16 
identifying genetic and environmental contributions to health and disease (11). Several brain- 17 
related traits and diseases are associated with variation in DNAm. MDD, a moderately 18 
heritable disorder, has been associated with differential methylation at several CpG sites, 19 
with a methylation risk score explaining 1.75% of the variance in the disorder (12). Further, in 20 
an epigenome-wide association study (EWAS) using blood, CpG sites associated with 21 
depressive symptoms were annotated to genes involved in axonal guidance (13). 22 
Schizophrenia has been associated with epigenetic variation at multiple loci that contribute 23 
to the polygenicity of the disorder (14,15). Finally, growing evidence has shown that DNAm 24 
can act as a proxy for the biological age of multiple tissues across life (16). These studies 25 
indicate that it may be possible, in future, to utilise DNAm modifications as biomarkers for 26 
brain-related healthy traits and diseases and to identify novel mechanisms contributing to 27 
these traits. 28 
In recent years, increasing efforts have been made to identify epigenetic correlates of 29 




previous studies have focused on candidate genes and candidate epigenetic markers in 32 
relation to specific brain regions of interest, such as subcortical volumes in the hippocampus 33 
and amygdala, as well as cortical thickness and volume in Freesurfer-derived brain regions 34 
(18), although consistency between study findings is modest. Recent advances in high- 35 
throughput array technologies that can identify DNAm levels at over 450K and 850K locations 36 
along the genome have enabled researchers to identify DNAm-brain associations using a 37 
hypothesis-free approach using EWAS (19). DNAm modifications in relation to brain 38 
phenotypes have also been identified in patients as opposed to healthy individuals, including 39 
in the frontal cortex in schizophrenia (20,21), hippocampal volume in MDD (22), in the 40 
cerebral cortex in Alzheimer’s disease (23), and in the frontal cortex in Parkinson’s disease 41 
(24). Structural brain measures may therefore function as endophenotypes that can be used 42 
to assess the association between epigenetic modifications and brain health and disease. 43 
The pathogenesis of psychiatric and neurodegenerative disorders has been associated 44 
with a multitude of cortical and subcortical brain regions with inconsistent results across 45 
studies (3,25–27), potentially indicating a role for whole-brain abnormalities in these 46 
disorders. Peripheral DNAm alterations associated with clinically relevant global brain 47 
structure may therefore further our mechanistic understanding of brain anatomy in both 48 
health and disease, may help to identify modifiable risk factors and may form a basis for the 49 
development of more accurate predictive risk scores capturing a wider array of potential 50 
influences. 51 
The majority of the studies mentioned above used whole blood as a surrogate tissue 52 
for the brain due to inaccessibility of the brain ante-mortem. Although DNAm is reported to 53 
be tissue- and cell type-specific, similarities between blood and brain DNAm have also been 54 
identified (28). In addition, whole blood has successfully been used in the past to identify 55 
meaningful epigenetic differences in brain-related traits, as shown above (18). 56 
Here, we sought to assess DNAm associations with Magnetic Resonance Imaging (MRI) 57 
global brain structural phenotypes, including cerebral white matter, total grey matter, and 58 
whole-brain volume using the Illumina Infinium MethylationEPIC array, capturing DNAm at 59 
approximately 850K CpG sites (29). Using DNAm measured ~6 years prior to MRI data 60 
collection, we examined whether CpG sites were associated with global brain structure at a 61 
later timepoint in N=672 individuals. We then investigated whether concurrently measured 62 
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Study population: Generation Scotland: Scottish Family Health Study (GS:SFHS) 66 
GS:SFHS is a large, family-based epidemiological study aiming to investigate the 67 
genetics of health and disease in approximately 24,000 individuals aged 18-98 years across 68 
Scotland. Data collected between 2006 and 2011 consists of genetic, DNA methylation, and 69 
environmental variables (30,31). GS:SFHS received ethical approval from NHS Tayside 70 
Research Ethics Committee (REC reference number 05/S1401/89) and has Research Tissue 71 
Bank Status (reference: 20/ES/0021). Written informed consent was obtained from all 72 
participants. 73 
A total of N=9,618 participants from GS responded when re-contacted at a later 74 
timepoint, and further data on mental health, specifically depression, was obtained. N=1,188 75 
were recruited for brain scanning, and approximately N=700 with both DNAm and 76 
neuroimaging data were available at the time of the current study. Details of recruitment and 77 
study information have been reported previously (32,33). The study was supported by the 78 
Wellcome Trust through a Strategic Award (reference 104036/Z/14/Z). Written consent at 79 
each stage of the study was obtained from all participants. 80 
Two timepoints were used for the current study: blood samples were collected at 81 




Global brain volumes 86 
T1 images were processed using standard ENIGMA protocols (34) with FreeSurfer 5.3 87 
and all output was visually quality checked. Manual edits were applied as required to 88 
correct for inclusion of skull tissue, exclusion of brain tissue or for errors in parcellation. 89 
Global measures were extracted from the final output following all edits. Manual editing, 90 
although necessary, did introduce a degree of subjective bias, therefore 'editing' was 91 
included as a binary covariate (values: yes/no). Further, as the complete set of T1s was 92 
processed, quality checked and edited in two parts, 'batch' was also included as a covariate. 93 
9 
We used 3 global volume measures in the current study. Total cerebral white matter 94 
includes hyperintensities and excludes anything that is not white matter. Total grey matter is 95 
rendered by the sum of the cortex within the left and right hemispheres, as well as subcortical 96 
and cerebellar grey matter. Finally, whole-brain volume includes both grey and white matter, 97 
and corresponds to brain volume without the brain stem, ventricles, cerebrospinal fluid, and 98 
choroid plexus. 99 
 100 
Baseline lifestyle factors and MDD status 101 
Body mass index (BMI) was calculated using height (m) and weight (kg) as measured 102 
by clinical staff at baseline recruitment. Participants were asked to report the number of units 103 
of alcohol consumed during the past week and their smoking status (never, former, current); 104 
pack years was used to measure heaviness of smoking in current smokers by multiplying the 105 
number of cigarette packs (20 cigarettes/pack) smoked per day by the number of years a 106 
person has smoked (35). MDD status was assessed at baseline using the Structured Clinical 107 
Interview of the Diagnostic and Statistical Manual, version IV (SCID) (36). Participants with no 108 
MDD were defined as those individuals who did not fulfil criteria for a current or previous 109 
MDD diagnosis following the SCID interview. 110 
 111 
Concurrent lifestyle factors and MDD status 112 
At the follow-up assessment, participants were sent study packages that included 113 
questionnaires. Here, BMI was calculated using height (m) and weight (kg). Participants also 114 
recorded the number of units consumed during the past week, whether they were current, 115 
former, or non-smokers, and (if they smoked) the number of cigarettes smoked in an average 116 
week. Finally, MDD status was ascertained through the Composite International Diagnostic 117 
Interview-Short Form (CIDI-SF) (37), and participants with no MDD were those individuals 118 
who did not fulfil criteria for current or previous MDD diagnoses based on responses. 119 
 120 
DNA methylation 121 
Baseline DNAm data was pre-processed and quality-checked for all individuals by 122 
Amador et al. in 2019 (38). At the concurrent timepoint, samples were placed on the array 123 
10 
at two different time points and were therefore processed separately. The main difference 124 
between processing and analysis pipelines related to how key covariates were adjusted for. 125 
At baseline these were regressed out during pre-processing, whereas for the concurrent 126 
batches they were included as covariates in downstream analyses. However, across all 127 
batches, standard quality check (QC) and pre-processing steps with regards to sample and 128 
probe exclusions were identical (see below). We note however that differences in the 129 
processing resulted in different numbers of final CpG sites included for analysis. 130 
Cross-reactive (N=42,558) and polymorphic (N=10,971) CpGs, obtained from 131 
McCartney et al. (2016) were removed from both the baseline and concurrent DNAm datasets 132 
(39) .133 
Baseline DNA methylation 134 
Genome-wide DNAm data profiled from whole blood samples was available for 135 
9,873 individuals in GS:SFHS using the Illumina Human-MethylationEPIC BeadChip (29). 136 
Samples were obtained and DNA was extracted between 2006-2011. DNAm profiling using 137 
the Illumina Human-MethylationEPIC BeadChip (29) was performed in two sets (in 2016, set 138 
AN=5101; in 2019, set BN=4,450) and pre-processing and QC was conducted once the second 139 
set was released, as detailed in Amador et al. (38,40,41). Participants were removed due to 140 
a number of reasons, including sex mismatch (Nremoved=24), having more than 1% CpG sites 141 
with a detection p-value>0.05 (Nremoved=52), being an outlier for bisulphite conversion 142 
control probes (Nremoved=1), having a median methylated signal intensity more than 3 143 
standard deviations lower than expected (Nremoved=74), and other technical and dataset-144 
specific issues (Nremoved=602, see Supplementary Materials). A total of 10,495 CpG sites were 145 
removed due to low beadcount, poor detection p-value, and sub-optimal binding. 146 
R package “minfi” was used to read in the IDAT files, compute M and beta values, and 147 
remove probes with large detection p-values, and to compute principal components (PC) of 148 
control probes. Correction was then applied for (1) technical variation, where M values were 149 
included as outcome variables in a mixed linear model adjusting for appointment date and 150 
Sentrix ID (random effects), jointly with Sentrix position, batch, clinic, year, weekday, and 10 151 
PCs (fixed effects); and (2) biological variation by fitting residuals of (1) as outcome variables 152 
in a second mixed linear model adjusting for genetic and common family shared 153 
11 
environmental contributions (random effects classed as G: common genetic; K: kinship; F: 154 
nuclear family; C: couple; and S: sibling) and sex, age, and estimated cell type proportions 155 
(CD8T, CD4T, NK, Bcell, Mono, Gran) (fixed effects) (42). The final number of CpG sites that 156 
converged for these analyses was 674,246 across the 22 autosomes. 157 
 158 
Concurrent DNA methylation 159 
Genome-wide DNAm data profiled from whole blood samples was available for a total 160 
of 710 individuals using the Illumina Human-MethylationEPIC BeadChip (29). Pre-processing 161 
was carried out in two separate sets (Nset 1=404; Nset 2=306) intended as discovery and 162 
replication datasets, by Walker et al. (43,44). Meffil (45) was use to remove samples if: there 163 
was a mismatch between self-reported and methylation-predicted sex and if >0.5% of probes 164 
failed the detection p- value threshold (>0.01); probes were removed if >1% samples failed 165 
the detection p- value >0.01 and if >5% of samples failed the beadcount threshold (N=3). In 166 
addition, samples were removed if they showed evidence of dye bias and they were outliers 167 
for the bisulphite conversion control probes. ShinyMethyl (46) was then used to plot the log 168 
median intensity of methylated and unmethylated signals per array and inspect the output 169 
from the control probes; outlying samples detected by visual inspection were excluded. 170 
Meffil (45) was then used again to remove any additional samples who had a sex mismatch. 171 
PC plots were made using the first two methylation principal components and any additional 172 
outlying samples on the basis of these plots were removed. Finally, data were normalised 173 
using the dasen method in wateRmelon, and M-values were generated using the beta2m 174 
function in lumi (47). The final number of CpG sites after pre-processing was N=768,068 (set 175 
1) and N=765,695 (set 2) across the 22 autosomes. 176 
 177 
Statistical methods 178 
 179 
Epigenome-wide association 180 
We used the “limma” package (48) in R to run linear regression models for both 181 
baseline and concurrent DNAm data, where each CpG was included as an outcome variable. 182 
Brain cortical volumes, specifically cerebral white matter, total grey matter, and whole brain 183 
volume were included as predictor variables in separate EWAS at each DNAm timepoint. 184 
12 
The R code for these analyses is available in the Supplementary Materials. 185 
Covariates for each model using baseline DNAm were MRI site (to account for 186 
different data collection sites; see Supplementary Materials), age, age2, sex, intracranial 187 
volume, and set (to account for different DNAm data pre-processing sets). Due to the impact 188 
of lifestyle factors on DNAm (49–52), BMI, alcohol units, smoking status, and pack years 189 
were also included as covariates. Lastly, due to the increased prevalence of MDD in the 190 
dataset, MDD status was included as a covariate in all models. Technical (batch, 191 
appointment date) and biological (relatedness, cell type estimations, methylation principal 192 
components) variables were regressed out during pre-processing and were not included as 193 
covariates in downstream analyses. After QC, there were 674,246 CpGs and epigenome-194 
wide significance was determined by a Bonferroni correction (0.05/674,246, p≤7.41×10−8). 195 
For both sets at the concurrent DNAm timepoint, covariates for each model were 196 
DNAm batch, 5 cell type proportion estimations (granulocytes, natural killer cells, B- 197 
lymphocytes, CD4+ T-lymphocytes and CD8+ T-lymphocytes), MRI site, age, age2, sex, 198 
intercranial volume, BMI, smoking status, number of cigarettes smoked/week, alcohol units, 199 
MDD status, and 20 methylation PCs. Bonferroni correction was applied based on the number 200 
of CpGs remaining in each set after QC (set 1: 0.05/768,068 CpGs, p≤6.51x10-8; set 2: 201 
0.05/765,695 CpGs, p≤6.52x10-8). 202 
The Blood Brain DNA Methylation Comparison Tool (53) 203 
(http://epigenetics.essex.ac.uk/bloodbrain/) investigates the correlation between DNAm 204 
from whole blood and four brain regions (prefrontal cortex, entorhinal cortex, superior 205 
temporal gyrus, and cerebellum) for all probes on the Illumina 450K array (54). We used this 206 
resource to investigate the strength of correlation between the two tissues for CpGs identified 207 
here. 208 
 209 
Meta-analysis using METAL – concurrent timepoint 210 
At the concurrent timepoint, in set 1, N=331 individuals were available with global 211 
volume and methylation data after QC and N=234 were available in set 2. Meta-analysis of 212 
these two datasets was performed in METAL (55) using p-value based analysis (N=565). The 213 
meta-analysis was based on N=769,263 CpGs across both sets and a Bonferroni correction 214 
13 
(0.05/769,263) was used to define epigenome-wide significance (p≤6.49x10-8). 215 
Pathway analysis 216 
We annotated CpG sites to genes through the Infinium MethylationEPIC BeadChip 217 
database (29). The database provides information about genes, chromosome location, start 218 
and end sites, and other features. 219 
We used missMethyl (56), accessed via methylGSA (57), to assess pathway enrichment 220 
for differentially-methylated CpG sites. The package allows correction for biases in the 221 
representation of genes on the Infinium BeadChip. Gene Ontology (GO) terms were accessed 222 
using the msigdbr package (58). Pathways included in the analysis were all GO pathways of 223 
size 1-250 genes inclusive. CpG sites included in the analysis were those significant at a 224 
threshold of p<1x10-5, as used in previous studies (59). Information on GO pathways can be 225 
accessed via www.geneontology.org using Gene Ontology identifiers, comprised of “GO” 226 
followed by a string of numbers (e.g. GO:0000000). 227 
 228 
Power analysis – concurrent timepoint 229 
Since the concurrent data was formed by two smaller samples of pre-processed 230 
data, we additionally conducted power analysis to determine whether our concurrent 231 
samples had sufficient power to detect a significant effect. This was conducted using effect 232 
sizes from the baseline data to inform the power calculations. We used the “pwr.f2.test” 233 
function in package “pwr” in R and the set parameters were as follows: 234 
1. Regression coefficients: DNAm batch, 5 cell type estimations (granulocytes, 235 
natural killer cells, B-lymphocytes, CD4+ T-lymphocytes and CD8+ T-lymphocytes), MRI site, 236 
age, age2, sex, intercranial volume, BMI, smoking status, number of cigarettes 237 
smoked/week, alcohol units, MDD status, 20 methylation principal components. 238 
2. Effect size: we input the largest effect size identified in EWAS at baseline (N=672) 239 
for each global volume. 240 
3. Significance level: to adjust for multiple testing correction (FDR), the p-value for a 241 
single potential test was set based on the number of CpG sites in each dataset (set 1: 242 
0.05/768,068=6.51x10-8; set 2: 0.05/765,695=6.53x10-8). 243 
14 
4. Power: to observe different power percentages, we input 60%, 80%, 90%, 95% 244 




Demographic characteristics 248 
There were N=672 individuals in the baseline EWAS, N=331 in the set 1 concurrent 249 
EWAS, and N=234 in the set 2 concurrent EWAS. Demographic characteristics for all 250 
individuals are presented in Table 1. Further descriptive characteristics regarding global 251 
volumes are presented in Supplementary Table 1. 252 
Demographic 
characteristics Baseline (N=672) 
Concurrent set 1 
(N=331)
Concurrent set 2 
(N=234) 
Age – Mean (SD), range 52.29 (9.93), 18-75 60.45 (8.42), 28-78 59.61 (10.21), 28-81
Sex    
Female 406 193 132 
Male 266 138 102 
Set    
1 621 - - 
2 51 - - 
BMI – Mean (SD), range 27.13 (4.96), 15.96- 
56.60 
27.48 (5.18), 16.42- 
51.75 
28.23 (5.31), 19-20- 
52.81 
Alcohol units – Mean 
(SD), range 10.53 (16.44), 0-326 7.12 (8.91), 0-60 7.39 (9.67), 0-60 
Smoking status    
Current smoker 83 16 12 
Former smokers (quit < 





Former smokers (quit > 
1 year ago) 208   
Never smoked tobacco 371 191 130 
Pack years – Mean (SD), 
range 7.59 (14.56), 0-111 - - 
Cigarettes 
smoked/week    
1-10 cigarettes - 10 6 
11-20 cigarettes - 10 9 
MDD status    
Cases 121 83 83 
Controls 551 248 151 
Table 1. Demographic characteristics for individuals with global volume data, including 253 
lifestyle variables and MDD. “-“ indicates that there was no data of the sort for the 254 
respective dataset. Former smokers at the baseline measurement were split into those who 255 
quit less than a year ago and those who quit more than a year ago; at the concurrent 256 




Baseline EWAS 260 
Baseline EWAS identified 1, 3, and 2 CpG sites that were associated with cerebral 261 
white matter, total grey matter, and whole-brain volume, respectively (p≤7.41x10-8). Both 262 
CpGs associated with whole brain volume were also associated with total grey matter and 263 
were significantly hypermethylated. One CpG site associated with cerebral white matter and 264 
one associated with total grey matter were hypomethylated. As shown in Figure 1A-C, CpG 265 
associations with grey matter were stronger than with white matter. Information about each 266 
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(p=8x10-21 p=3x10-14; (60)) 
Heel bone mineral density 
(p=2x10-12; (61)) 
Intelligence (p=1x10-11; (62)) 
Self-reported educational 
attainment (p=8x10-11; (63)) 
Cognitive function 
measurement (p=2x10-9; (63)) 
Mathematical ability (p=3x10- 9; 
(63)) 
Smoking status measurement 
(p=7x10-9; (64)) 



















































Involved in DNA repair;
mutations at locus associated 
with microcephaly, seizures, 































attainment (p=2x10-20; (63)) 
Mathematical ability (p=1x10- 
17; (63)) 
Cognitive function 
measurement (p=3x10-12; (63)) 
Schizophrenia (p=3x10-12; (67)) 
 269 
Table 2. CpG sites significantly associated with cerebral white matter, total grey matter, and 270 
whole-brain volume (N=672), along with gene annotations (Gene), chromosome (C), 271 
17 
standardised effect size (β), nominal (P-value) and multiple comparison-corrected p-values 272 
(P-corr). Traits previously associated with each CpG site were extracted from EWAS 273 
catalogues (http://www.ewascatalog.org/, association between traits and CpGs on Illumina 274 
450K array at p≤1.0x10-4; and http://www.bioapp.org/ewasdb/, (68)), association between 275 
traits and CpGs on Illumina 450K and EPIC arrays at p≤1.0x10-3). Gene information was 276 
extracted from the GWAS catalogue (https://www.ebi.ac.uk/gwas/; associations between 277 
traits and SNPs at p < 1.0x10- 5). All associations included in the table from these two 278 




Figure 1A, 1B, 1C. Manhattan plots showing the results from EWASs of cerebral white matter 282 
(1A), total grey matter (1B), and whole-brain volume (1C), using baseline DNAm data (N=672). 283 
The black line defines the threshold for epigenome-wide significance (p≤7.41x10-8) and the 284 
dotted line defines CpG sites at p≤1x10-5. Epigenome-wide significant hits for each phenotype 285 
are labelled on the graph. 286 
19 
Correlation between whole blood DNAm and four brain regions 287 
We used the Blood Brain DNA Methylation Comparison Tool (53) to investigate the 288 
correlation between blood and brain methylation measurements for two of the CpGs 289 
identified here, located on the 450K array, and four brain regions. cg04190002 was strongly 290 
correlated with prefrontal cortex (r=0.579, p=6.55x10-8), entorhinal cortex (r=0.564, 291 
p=2.94x10-7), superior temporal gyrus (r=0.598, p=1.5x10-8), and cerebellum (r=0.663, 292 
p=3.02x10-10), while cg02325951 was strongly correlated with prefrontal cortex (r=0.858, 293 
p=1.73x10-22), entorhinal cortex (r=0.868, p=1.19x10-22), and superior temporal gyrus 294 
(r=0.871, p=3.32x10-24). 295 
 296 
Baseline Pathway Analysis 297 
Enrichment of differentially methylated regions in biological pathways was analysed 298 
using missMethyl (56), where an over-representation analysis of GO pathways was performed 299 
for sets of genes annotated to CpG sites differentially expressed at p<1x10-5 (Ncerebral white matter: 300 
19, Ntotal grey matter: 22, Nwhole-brain volume: 21). 301 
There were no over-represented pathways after multiple correction. A number of 302 
brain-related biological processes, molecular functions, and cellular components were 303 
included in the top 10 significant pathways (Supplementary Table 2). For instance, guanylate 304 
kinase-associated protein clustering, which facilitates assembly of post-synaptic density of 305 
neurons (GO:0097117), was found to be over-represented for all three imaging phenotypes 306 
(cerebral white matter nominal p-value=0.0007; total grey matter nominal p-value=0.001; 307 
whole-brain volume nominal p-value=0.0009). Positive regulation of synapse structural 308 
plasticity (GO:0051835) was over-represented in both cerebral white matter (nominal p-309 
value=0.002) and total grey matter (nominal p-value=0.002). Finally, forebrain generation of 310 
neurons (GO:0021872; nominal p-value=0.001) was over-represented for cerebral white 311 
matter. 312 
 313 
Concurrent EWAS 314 
Meta-analysis of EWAS across the two concurrent sets did not reveal any Bonferroni-315 
corrected CpG sites associated with any of the global volumes (Figure 2A-C). A list of the top 316 
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10 CpGs associated with cerebral white matter (EWASset 1 βrange=4.71x10-6- 6.53x10-6; 317 
EWASset 2 βrange=1.02x10-5-8.75x10-6) total grey matter (EWASset 1 βrange=6.71x10-6-8.03x10-6; 318 
EWASset 2   βrange=1.03x10-5-8.84x10-6), and whole-brain volume (EWASset 1 βrange=2.69x10-319 
6-4.05x10-6; EWASset 2 βrange=6.23x10-6-6.69x10-6), is presented in Supplementary Tables 3-5. 320 
Genes annotated to these top 10 CpGs have previously been implicated in brain-related 321 
phenotypes, including psychiatric disorders (MDD (69–72), schizophrenia (73)), 322 
neurodegenerative disorders (neurofibrillary tangles and PHF-tau measurement in 323 
Alzheimer’s Disease (74)), and cognitive traits (mathematical ability, self- reported 324 
educational attainment (75)). Results reported here are nominal and should be supported 325 
by further large-scale cohorts.326 
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 327 
Figure 2A, 2B, 2C. Manhattan plots showing meta-analysis of EWAS of cerebral white matter 328 
(2A), total grey matter (2B), and whole-brain volume (2C), across the 2 concurrent sets (Nset 329 
1=331; Nset 2=234; Ntotal=565). The black line defines the threshold for epigenome-wide 330 
significance (p≤6.5x10-8) and the dotted line defines p≤1x10-5. CpGs that met a significance of 331 
p≤1x10-5 are labelled on the graph. 332 
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Concurrent Pathway Analysis 333 
As above, enrichment of differentially methylated regions in specific pathways was 334 
assessed using missMethyl (50) for sets of genes annotated to CpG sites differentially 335 
expressed at p<1x10-5 (Ncerebral white matter: 10, Ntotal grey matter: 10, Nwhole-brain volume: 9). There were 336 
no over-represented pathways following FDR adjustment for multiple comparisons. The top 337 
10 most significant pathways for each phenotype indicated a pattern of phenotype-specific 338 
biological processes, molecular functions, and cellular components (Supplementary Table 6). 339 
For instance, over-represented pathways in cerebral white matter included myelination 340 
(GO:0042552; nominal p-value=0.002), ensheathment of neurons (GO:0007272; nominal p-341 
value=0.002), axon ensheathment (GO:0008366; nominal p-value=0.001), glial cell 342 
development (GO:0021782; nominal p-value=0.001) and glial cell differentiation 343 
(GO:0010001; nominal p-value=0.004). Total grey matter over-represented pathways 344 
included glutamate catabolic process to aspartate (GO:0019550; nominal p-value=0.0009) 345 
and to 2-oxoglutarate (GO:0019551; nominal p-value=0.0009). Finally, over-represented 346 
pathways in whole-brain volume included several MHC-related biological processes, including 347 
regulation (GO:0002586; nominal p-value=0.001) and negative regulation (GO:0002587; 348 
nominal p-value=0.0009) of antigen processing and presentation of peptide antigen via MHC 349 
class II, negative regulation of antigen processing and presentation of peptide or 350 
polysaccharide antigen via MHC class II (GO:0002581; nominal p-value=0.001), as well as N- 351 
acetyllactosaminide beta-1,3-N-acetylglucosaminyltransferase (GO:0008532, molecular 352 
function, nominal p-value=0.001), an enzyme encoded by the gene B3GNT2, which is highly 353 
expressed in whole-brain, hippocampus, amygdala, cerebellum, and caudate nucleus 354 
(https://www.uniprot.org/uniprot/Q9Z222). 355 
 356 
Power curves for concurrent data 357 
Power curves for the three imaging phenotypes are presented in Figure 3. Further 358 
details, including effect size for each phenotype, are included in Supplementary Tables 7 and 359 
8. These indicate that approximately 1,000-6,000 individuals (depending on phenotype) 360 





Figure 3. Power curves for cerebral white matter, total grey matter, and whole-brain volume 365 
calculated separately for set 1 and set 2. The x-axis indicates how many participants would 366 
be needed to detect an effect with 60%, 80%, 90%, 95% or 99% power at p<6.51x10-8 (set 1 367 
(W1)) and p<6.53x10-8 (set 2 (W2)) with 36 regression coefficients included in the linear 368 
model. Effect sizes were calculated based on the largest effect size obtained in EWAS for each 369 
phenotype at baseline. 370 
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Discussion 371 
We report a number of significant associations between DNAm measured ~6 years 372 
prior to MRI data collection and cerebral white matter (Nsignificant CpGs=1), total grey matter 373 
(Nsignificant CpGs=3), and whole-brain volume (Nsignificant CpGs=2) (N=672), annotated to genes 374 
involved in brain-related traits. There were no significant associations between DNAm 375 
collected concurrently with MRI data (N=565). In addition, pathway analysis did not uncover 376 
any significant findings for either the baseline or concurrent analyses. Power analysis of the 377 
concurrent data using baseline data for effect size confirmed that approximately 1,000-378 
6,000 individuals (depending on phenotype) would be needed to detect a statistically 379 
significant effect. 380 
For the analysis of associations between DNAm measured at baseline and cortical 381 
volumes ~6 years later, one CpG associated with cerebral white matter, cg10297662, was 382 
annotated to PNKP. This CpG site has not previously been associated with any other traits, to 383 
the best of our knowledge. PNKP is involved in DNA repair following ionizing radiation or 384 
oxidative damage (76) and is expressed in a number of tissues, including the brain. 385 
Mutations in this gene have been associated with a number of neural conditions, including 386 
microcephaly, developmental delay, seizures, and cerebellar ataxia (66,77). These mutations 387 
have been shown to lead to white matter defects, which is the phenotype investigated here 388 
(78). Previous evidence also indicates that loss of PNKP strongly impacts oligodendrocytes, 389 
leading to white matter abnormalities (79). Efforts should be made to identify whether the 390 
relationship between PNKP mutations and defects in white matter is mediated by 391 
differential DNAm at specific sites. 392 
Two CpGs, cg07585845 and cg02325951, were associated with both total grey matter 393 
and whole-brain volume. cg07585845 has not been previously associated with any traits nor 394 
annotated to any genes. cg02325951 was previously associated with sex in a study 395 
investigating methylation trajectories across human foetal brain development (p=2x10-54; 396 
(80)). The gene to which cg02325951 is annotated, FOXN3, is involved in several physiological 397 
processes, such as development, ageing, obesity, and cancer and is expressed in multiple 398 
tissues, including the forebrain and midbrain. Further, animal studies show that mutations 399 
within the gene have been associated with craniofacial defects (81). In addition, FOXN3 has 400 
previously been associated with several brain-related phenotypes in previous GWAS, 401 
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including intelligence (p=1x10-11; (62)), self-reported educational attainment (p=8x10-11), 402 
cognitive function measurement (p=2x10-9), and mathematical ability (p=3x10-9) (63). These 403 
cognition-related phenotypes have previously been associated with whole brain volume, 404 
where higher cognition was associated with a larger brain size (76). Future studies should 405 
investigate whether DNAm localized to FOXN3 plays a role in cognition development 406 
through modifications in whole-brain volume. 407 
Finally, in addition to the two CpGs above, total grey matter was also associated with 408 
cg04190002, a CpG previously associated with sex in newborns (p=5.4x10-19; (82)). The CpG is 409 
annotated to SHANK3, which encodes multidomain scaffold proteins of the postsynaptic 410 
density connecting neurotransmitter receptors, among other membrane proteins and is 411 
expressed in the cerebral cortex and the cerebellum. The gene has previously been 412 
associated with a host of brain disorders and traits, including self- reported educational 413 
attainment (p=2x10-20), mathematical ability (p=1x10-17), cognitive function measurement 414 
(p=3x10-12) (63) and schizophrenia (p=3x10-9; (67)), and mutations have previously been 415 
associated with autism spectrum disorder (83). These disorders in turn have been 416 
associated with changes in grey matter (84), and future studies should investigate whether 417 
these psychiatric disorders are also associated with differential DNAm at cg04190002, and 418 
other probes localized to SHANK3, as well as explore whether associations are mediated by 419 
global brain phenotypes. 420 
Blood and brain methylation measures for both cg02325951 and cg04190002 (both 421 
CpGs on the 450K array) were strongly correlated, indicating that whole blood is a suitable 422 
proxy tissue for investigating associations with brain phenotypes, at least for these probes. 423 
Future studies exploring DNAm in relation to global brain phenotypes and associated traits 424 
may therefore benefit from whole blood DNAm measurements. 425 
DNAm profiled at a different timepoint to phenotype measurement has previously 426 
yielded interesting results. Barbu et al. (2020) found that a methylation risk score calculated 427 
from DNAm profiled 4-11 years prior to MDD diagnosis was significantly associated with 428 
incident cases who were well at DNAm measurement but went on to develop MDD (12). Clark 429 
et al. (2020) similarly associated DNAm profiled in MDD patients at baseline with MDD status 430 
6 years later (85). These previous findings indicate that DNAm measured prior to phenotype 431 
measurement may provide meaningful insight into phenotype development and change 432 
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across time. The findings above relating DNAm measured previously to MRI scans may 433 
therefore aid in the investigation of epigenetic differences in brain-related disease and health 434 
at a later timepoint, although further longitudinal replication is needed to verify these 435 
associations. 436 
Associations between DNAm measured concurrently to MRI scans did not yield any 437 
significant findings. Power calculations using the baseline data to derive effect size showed 438 
that approximately 1,000-6,000 participants (depending on phenotype) would be needed to 439 
uncover a significant effect at epigenome-wide level. This number is supported by previous 440 
studies, such as Jia et al. (2019), who analysed 3,337 individuals across 11 cohorts as part of 441 
ENIGMA to find 2 CpGs significantly associated with hippocampal volume (19). This may 442 
indicate that null findings were due to lack of power at the concurrent timepoint. Null 443 
findings here should serve as a stimulus for larger collaborations and meta-analyses in 444 
future. 445 
Further, effect sizes for both timepoints were much smaller than those identified in 446 
previous studies that analysed larger sample sizes in specific brain regions (19) (largest 447 
baseline effect size: 1.46x10-6; largest concurrent effect size: 1.06x10-6), which suggests that 448 
findings here should be interpreted with caution. The results here indicate that global 449 
associations with DNAm may be weaker than those at a regional level. Future studies may 450 
therefore benefit from focussing on lobe- and region-specific correlates of DNAm. 451 
At the concurrent timepoint, DNAm data was pre-processed and quality-checked in 2 452 
sets, resulting in a different number of final CpGs (NCpG set 1=768,068; NCpG set 2=765,695). 453 
Pearson’s correlations between the EWAS betas from set 1 and set 2 across all CpGs were 454 
r=0.02 (95% C.I.=0-0.102), r=0.04 (95% C.I.=0-122), and r=0.03 (95% C.I.=0-0.112) for 455 
cerebral white matter, total grey matter, and whole brain volume, respectively. When 456 
restricting CpGs to those with a nominal p-value (≤0.05), the beta correlations were slightly 457 
higher, although not strong: r=0.17 (95% C.I.=0.089-0.249), r=0.18 (95% C.I.=0.099-0.259), 458 
and r=0.22 (95% C.I.=0.14-0.297) for cerebral white matter, total grey matter, and whole-459 
brain volume, respectively. The low effect size correlations may be a further reflection of the 460 
small sample investigated here. 461 
There are limitations to the current study. Firstly, we report DNAm changes in whole 462 
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blood, which may not be representative of brain phenotypes. However, two of the CpGs 463 
identified here, located on the 450K array, were strongly correlated with DNAm in four brain 464 
regions (53). Although previous studies have shown that there is considerable agreement 465 
between blood and brain (28), future studies should explore DNAm changes in the brain in 466 
post-mortem samples where possible to uncover biological mechanisms underpinning brain 467 
structure within the same tissue. Further, findings at baseline may indicate that some DNAm 468 
changes lie upstream of brain structural changes, although effect sizes for each CpG were 469 
small compared to previous concurrent EWAS of brain regions (18,19). In addition, we 470 
cannot test the direction of association between brain structural changes and DNAm. In 471 
future, studies may apply Mendelian Randomization to investigate whether DNAm may be 472 
on the causal path to brain structure alterations in brain health and disease. Finally, in the 473 
current study we focussed on global brain phenotypes to explore whether global brain-474 
related changes, previously associated with psychiatric and neurological disorders, are 475 
associated with DNAm alterations. Previous evidence includes DNAm associations at both 476 
global and regional level (18), and it may be that DNAm may provide more insight into 477 
region-specific alterations in relation to brain health and disease.  478 
In conclusion, we report an EWAS of global cortical brain volumes using DNAm data 479 
collected ~6 years prior to MRI data collection in 672 individuals and an EWAS meta-analysis 480 
of cortical brain volumes using DNAm measured concurrently to MRI data in 565 individuals, 481 
both part of a large, population-based cohort. Using baseline DNAm data, we find four CpGs 482 
significantly associated with cortical brain volumes ~6 years later, all of which are annotated 483 
to genes implicated in brain-related phenotypes. We did not find significant associations at 484 
the concurrent timepoint. Findings here should be interpreted with caution, and future 485 
studies should aim to determine further links between DNAm changes and brain structure 486 
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